Johnson & Johnson (JNJ) stock forecast · P/E 17, rev $49.37B
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
This JNJ forecast page states what the cached financials imply — not a price target and not a guarantee. Johnson & Johnson outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Period-over-period revenue change is not in cache for JNJ, so this page does not invent a growth rate.
JNJ currently screens at market cap $375.37B and trailing P/E 17.4. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next JNJ 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the JNJ stock page.
Not investment advice.